The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment.

Teva Pharmaceutical’s Copaxone was approved by the FDA in 1996 to treat relapsing forms of MS, an autoimmune disorder that ...

From 1996-2024, 82 cases of anaphylaxis associated with glatiramer acetate were reported to the FDA Adverse Event Reporting ...

The FDA has advised health care professionals and patients with multiple sclerosis that treatment with glatiramer acetate is ...

Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system. The Mayo Clinic says MS causes the breakdown of the protective covering of nerve fibers, known as ...

While most of us associate gluten intolerance with stomach upsets, it can also cause 'brain fog' as well as a range of other unexpected symptoms ...

FDA issues new warnings about rare but severe allergic reactions, including anaphylaxis, linked to MS drug glatiramer acetate, urging immediate medical attention.

The US Food and Drug Administration (FDA) is warning about the risk of a rare but serious allergic reaction with the medicine ...

Reports of anaphylaxis associated with the use of glatiramer acetate have prompted the Food and Drug Administration (FDA) to add a Boxed Warning to the prescribing information.

The drug could aid in the restoration of vision in those suffering from multiple sclerosis (MS) and other neurodegenerative diseases.

Over the years, the U.S. Department of Justice (DOJ) has taken a host of drugmakers to task over alleged kickback payments ...

Spain's Ministry of Health published the draft royal decree to allow the prescription of cannabis preparations back in ...